BOPI 06 BR/2023 REPERTOIRE NUMERIQUE 39 (11) 21024 (51) A61K 31/438 (2018.01); A61P 1/08 (2018.01); A61P 19/00 (2018.01); A61P 21/00 (2018.01); A61P 29/00 (2018.01); A61P 3/04 (2018.01); C07D 471/20 (2018.01); C07D 519/00 (2018.01) (21) 1202200515 - PCT/IB2021/054970 (22) 07/06/2021 (30) US n° 63/036,798 du 09/06/2020; US n° 63/167,271 du 29/03/2021 (54) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof. (72) SMITH, Aaron Christopher (US); BUTLER, Christopher Ryan (US); POLIVKOVA, Jana (US); SAMMONS, Matthew Forrest (US); YANG, Qingyi (US); GARNSEY, Michelle Renee (US) et OGILVIE, Kevin Alexander (US) (73) PFIZER INC., 235 East 42nd Street, NEW YORK, New York 10017 (US) (74) S.C.P AKKUM, AKKUM & Associates, n° 1777, Rue 6.261, Auditorium Jean Paul II, Quartier Mbankolo, B.P. 4966, YAOUNDE (CM). (57) Described herein are compounds of Formula I : and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts. Formula I Consulter le mémoire ________________________________________ (11) 21025 (51) A61P 31/20 (2018.01) ; C07K 16/08 (2018.01) (21) 1202200535 - PCT/US2021/038667 (22) 23/06/2021 (30) US n° 63/043,692 du 24/06/2020 (54) Engineered hepatitis B virus neutralizing antibodies and uses thereof. (72) CORTI, Davide (CH); ROSEN, Laura (US); CZUDNOCHOWSKI, Nadine (US); LEMPP, Florian A. (US); SNELL, Gyorgy (US) et CAMERONI, Elisabetta (CH) (73) 1-VIR BIOTECHNOLOGY, INC., 499 Illinois Street, Suite 500, SAN FRANCISCO, California 94158 (US) et 2-HUMABS BIOMED SA, Via dei Gaggini 3, 6500 BELLINZONA (CH)
RkJQdWJsaXNoZXIy MTM1NDc3MA==